Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 25931585
Zonta F, et al. (2015) Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood 125, 3747-55 25931585
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y307-p - PPP2CA (human)
Modsite: VTRRtPDyFl_____ SwissProt Entrez-Gene
Orthologous residues
PPP2CA (human): Y307‑p, PPP2CA iso2 (human): Y253‑p, PPP2CA (mouse): Y307‑p, PPP2CA (rat): Y307‑p, PPP2CA (pig): Y307‑p, PPP2CA (cow): Y307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  B lymphocyte
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate no change compared to control
dasatinib decrease
PP2 decrease
saracatinib decrease
geldanamycin decrease
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited, molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
ASH2L (human) Induces co-immunoprecipitation